根治性前列腺切除术对匹配队列中病理淋巴结阳性前列腺癌去势治疗患者长期肿瘤学结局的影响
研究匹配158例病理淋巴结阳性前列腺癌患者,比较根治性耻骨后前列腺切除术加睾丸切除术与单纯睾丸切除术的长期结局。前列腺切除术组20年癌症特异性生存59% vs 18%,总生存22% vs 9%,Cox模型HR分别为0.28和0.48。结论认为在技术可行且选择合适患者中,积极局部区域切除可作为多模式治疗的一部分考虑。
要点
- 前列腺切除术加睾丸切除术组20年癌症特异性生存59%,单纯睾丸切除术组18%。
- 前列腺切除术加睾丸切除术组20年总生存22%,单纯睾丸切除术组9%。
- Cox模型显示前列腺切除术加睾丸切除术与癌症特异性生存改善相关(HR 0.28)。
核心结论
- 在近全部队列终身随访中,病理淋巴结阳性前列腺癌在睾丸切除术基础上加根治性耻骨后前列腺切除术与癌症特异性和总生存改善相关。
- 作者认为,当技术可行且在选择良好的患者中,积极局部区域切除应作为淋巴结阳性前列腺癌多模式治疗的一部分予以考虑。
研究设计与样本
- 匹配队列研究,纳入1966年至1995年间因病理淋巴结阳性前列腺癌在90天内接受盆腔淋巴结清扫和睾丸切除术的男性。
- 将接受根治性耻骨后前列腺切除术加睾丸切除术的男性按年龄、手术年份、临床分级、临床T分期、阳性淋巴结数目和术前血清前列腺特异性抗原(后者自1987年起)与单纯睾丸切除术男性1:1匹配。
- 匹配队列共158例男性,每组79例。
主要发现
- 单纯睾丸切除术组76例死亡,其中60例死于前列腺癌;前列腺切除术加睾丸切除术组70例死亡,其中28例死于前列腺癌。
- Kaplan-Meier分析显示前列腺切除术加睾丸切除术 vs 单纯睾丸切除术与癌症特异性生存延长相关(20年时59% vs 18%,log rank p<0.001)。
- Kaplan-Meier分析显示前列腺切除术加睾丸切除术 vs 单纯睾丸切除术与总生存延长相关(20年时22% vs 9%,log rank p<0.001)。
- Cox模型显示前列腺切除术加睾丸切除术 vs 单纯睾丸切除术与癌症特异性生存改善相关(HR 0.28,95%CI 0.17-0.46,p<0.001)。
- Cox模型显示前列腺切除术加睾丸切除术 vs 单纯睾丸切除术与总生存改善相关(HR 0.48,95%CI 0.34-0.66,p<0.001)。
临床怎么用
- 作者认为,当技术可行且在选择良好的患者中,积极局部区域切除应作为淋巴结阳性前列腺癌多模式治疗的一部分予以考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Long-term data supporting the role of primary tumor resection in node positive prostate cancer are lacking. We evaluated the impact of adding radical retropubic prostatectomy to surgical castration on long-term oncologic outcomes in pathological node positive prostate cancer. MATERIALS AND METHODS: We identified men who underwent pelvic lymphadenectomy and orchiectomy within 90 days for pathological node positive prostate cancer from 1966 to 1995. Men treated with radical retropubic prostatectomy in addition to orchiectomy were matched 1:1 to men who underwent orchiectomy alone based on age, year of surgery, clinical grade, clinical T stage, number of positive nodes and preoperative serum prostate specific antigen, the latter from 1987 and thereafter. Kaplan-Meier and Cox regression analyses were done to compare cancer specific and overall survival. RESULTS: The matched cohort included 158 men with 79 in each group. Of men who underwent orchiectomy alone 76 died, including 60 of prostate cancer. Of patients treated with radical retropubic prostatectomy plus orchiectomy 70 died, including 28 of prostate cancer. On Kaplan-Meier analyses prostatectomy plus orchiectomy vs orchiectomy alone was associated with prolonged cancer specific survival (at 20 years 59% vs 18%, log rank p <0.001) and overall survival (at 20 years 22% vs 9%, log rank p <0.001). In Cox models prostatectomy plus orchiectomy vs orchiectomy alone was associated with improved cancer specific survival (HR 0.28, 95% CI 0.17-0.46, p <0.001) and overall survival (HR 0.48, 95% CI 0.34-0.66, p <0.001). Findings were similar in the subset with available preoperative prostate specific antigen values. CONCLUSIONS: With lifelong followup in nearly the entire cohort, this study demonstrates that adding radical retropubic prostatectomy to surgical castration for pathological node positive prostate cancer is associated with improved cancer specific and overall survival. When technically feasible in well selected patients, aggressive locoregional resection should be considered for node positive prostate cancer as part of a multimodal approach.
引用
- Bhindi B, Rangel LJ, Mason RJ, et al. Impact of Radical Prostatectomy on Long-Term Oncologic Outcomes in a Matched Cohort of Men with Pathological Node Positive Prostate Cancer Managed by Castration. J Urol. 2017. PMID: 28130104. doi:10.1016/j.juro.2017.01.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。